A growing number of adolescents suffer from mental illnesses such as anxiety, sadness, and Post-Traumatic Stress Disorder (PTSD), which can have a negative influence on their social, emotional, and cognitive development. Conventional pharmaceutical therapies frequently have drawbacks, such as adverse effects, low effectiveness, and noncompliance. A non-psychoactive substance obtained from Cannabis sativa, cannabidiol (CBD), has gained attention as a possible medicinal substitute because of its antidepressant and anxiolytic qualities. The purpose of this study was to examine how cannabidiol may be incorporated into adolescent psychiatry, with an emphasis on its therapeutic uses and safety-risk profile for the treatment of PTSD, depression, and anxiety. Electronic databases, including PubMed, Scopus, and Google Scholar, were used to do a thorough literature assessment. The effectiveness, safety, dose guidelines, and mechanisms of CBD in treating mental illnesses in teenagers were evaluated using an analysis of clinical trials, preclinical research, and observational reports released between 2019 and 2024. New research suggests that CBD interacts with the endocannabinoid system, serotonin receptors, and hippocampus neurogenesis, producing both anxiolytic and antidepressant effects. With minimal psychotropic effects, it may help reduce anxiety and PTSD symptoms. However, concerns about safety, particularly in teenage brains, arise from variations in formulations and a lack of long-term research. CBD may be used as a complementary or alternative therapy for PTSD, sadness, and anxiety in teenagers. However, to provide uniform recommendations and guarantee a safe transition into psychiatric treatment, thorough, long-term, and age-specific clinical studies are necessary.
Chauhan et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: